Cargando…
Targeting an engineered cytokine with interleukin-2 and interleukin-15 activity to the neovasculature of solid tumors
There is a growing interest in the antibody-based delivery of cytokines to the tumor environment as a means to boost the anti-cancer activity of tumor-resident T cells and NK cells. Here, we describe the expression and characterization of fusion proteins, featuring the L19 antibody (specific to the...
Autores principales: | Mortensen, Michael R., Mock, Jacqueline, Bertolini, Marco, Stringhini, Marco, Catalano, Marco, Neri, Dario |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7646832/ https://www.ncbi.nlm.nih.gov/pubmed/33216834 http://dx.doi.org/10.18632/oncotarget.27772 |
Ejemplares similares
-
A novel format for recombinant antibody-interleukin-2 fusion proteins exhibits superior tumor-targeting properties in vivo
por: Ongaro, Tiziano, et al.
Publicado: (2020) -
Cancer therapy in mice using a pure population of CD8(+) T cell specific to the AH1 tumor rejection antigen
por: Stringhini, Marco, et al.
Publicado: (2021) -
Vaccines targeting the neovasculature of tumors
por: Matejuk, Agata, et al.
Publicado: (2011) -
Antibody-mediated delivery of LIGHT to the tumor boosts natural killer cells and delays tumor progression
por: Stringhini, Marco, et al.
Publicado: (2021) -
Design and characterisation of a novel interleukin-15 receptor alpha fusion protein and analysis of interleukin-15 complexation
por: Schmid, Anja Sophie, et al.
Publicado: (2019)